Actinium Pharmaceuticals Inc. (ATNM) |
|
0.2042 -0.007 (-3.18%)
|
11-19 16:00 |
|
Open: |
0.21 |
Pre. Close: |
0.2109 |
|
High:
|
0.215 |
Low:
|
0.2 |
|
Volume:
|
1,608,750 |
Market Cap:
|
34M |
|
|
|
|
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.22 - 0.222 |
0.222 - 0.223 |
|
Low:
|
0.197 - 0.198 |
0.198 - 0.2 |
|
Close:
|
0.207 - 0.21 |
0.21 - 0.212 |
|
Technical analysis |
as of: 2019-11-19 4:24:22 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.38  One year: 0.48 |
| Support: |
Support1: 0.20 Support2: 0.16 |
| Resistance: |
Resistance1: 0.33 Resistance2: 0.41 |
| Pivot: |
0.25  |
| Moving Average: |
MA(5): 0.23 MA(20): 0.26
MA(100): 0.23 MA(250): 0.35 |
| MACD: |
MACD(12,26): Signal(9): 0.01 |
| Stochastic oscillator: |
%K(14,3): 13.84 %D(3): 17.29 |
| RSI: |
RSI(14): 39.70 |
| 52-week: |
High: 0.71 Low: 0.19 Change(%): -50.4 |
| Average Vol(K): |
3-Month: 150398 10-Days: 102888 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.ATNM has closed below the lower band by 6.8%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 34% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-11-07
Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference
NEW YORK , Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will attend the 25 th Annual BIO-Europe ® International Partnering …
2019-11-06
Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been accepted for presentation at the 2019 American Society of Hematology (ASH
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
